US2786014A - Platelet preservation - Google Patents

Platelet preservation Download PDF

Info

Publication number
US2786014A
US2786014A US308951A US30895152A US2786014A US 2786014 A US2786014 A US 2786014A US 308951 A US308951 A US 308951A US 30895152 A US30895152 A US 30895152A US 2786014 A US2786014 A US 2786014A
Authority
US
United States
Prior art keywords
platelets
matrix
gelatin
temperature
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US308951A
Inventor
James L Tullis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US308951A priority Critical patent/US2786014A/en
Application granted granted Critical
Publication of US2786014A publication Critical patent/US2786014A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • This invention relates to the preservation of platelets outside the living body and, more particularly, to sterile therapeutically effective preparations containing platelets in concentrated form, suitable for in-vivo use as in the field of platelet deficiency therapy.
  • the primary object of this invention was to devise a means by which platelets could be stockpiled for in-vivo use in case of catastrophic atomic radiation, though such stockpiling for peace-time therapy is alone a worthy object. To this end, it was imperative that platelet integrity outside the human body be prolonged, inasmuch as prior to this invention the stability of intactnessin the sense of preservation of therapeutic eflectiveness-of platelets outside living bodies did not exceed three days. Further objects include the preservation of platelets in a form suitable for injection into a living body at high concentratio'ns, for therapeutic purposes.
  • This invention further provides a practical preservative medium for highly concentrated platelets; and the platelet-containing preservative is in water-soluble and,
  • Platelets preserved in accordance with this invention are derived from whole blood by any of a variety of separation methods. Though constituting no part of this invention, exemplary separation techniques are:
  • Whole blood treated to prevent clotting as by the addition of citrate or other calcium sequestering agent, collected in a non-wettable surface sterile system and brought to a temperature near 0 C., may have its red and white cells sedimented with or Without the aid of 2.
  • Whole blood may be passed, without the additionof citrate, over a cation exchange resin on the sodium cycle, some of which sites have been covered with calcium, resulting in a nearly quantitative separation from the whole blood of the platelets with the calcium of'the .blood.
  • the platelets may be recovered fromthe exchange column by equilibrating the column with physiologi-c saline containing acetate ions and calcium complexing agents, all as described in an application of Edwin J. Cohn entitled Closed System for Continuous Separation of Components of Body Fluids, Serial No. 281,989, filed April 12, 1952.
  • the preservative medium of this invention may comprise an aqueous solution containing, per milliliters, about 0.2 gram of sodium acetate, about 5.0 grams glucose and about 0.9 gram sodium chloride.
  • the wet platelet yield from 500 milliliters of whole blood (being the spontaneous sediment from the saline solutions after decanting the supernatant), is then gently stirred into this mixture which is maintained at about 4 C.
  • sufiicient gelatin in a sterile pyrogen-free neutral aqueous solution so that, after standing, the composition will gel at a temperature of 4 C.
  • a Knox gelatin of about 60,000 molecular weight and about midway with respect to gelatin frac- Gelatin Between 0.3 and 1.2 grams.
  • Sodium chloride 0.36 gram.
  • the gelled platelet-containing preservative can be stored at 4 C. and may be brought to a condition for in-vivo use simply by raising to body temperature, at which temperature the gelatin reverts to a non-viscid liquid.
  • preparations of this invention when intended for in-vivo use, are prepared from sterilfl ized ingredients by aseptic techniques and using platelets derived from blood by aseptic and atraurnatic techniques.
  • the acetate anion acts as an anti-agglutina-te for the platelets.
  • Other organic acid radicals function in a similar manner and may be added in water-soluble salt forniL. Only small amounts of such anti-agglutinating agents 1 need be present, as no benefits appear to be derived with concentrations about the rangeiof 0.2-0.5 gram per 100 milliliters.
  • the glucose is an example of a hypertonicity-in-creasing agent.
  • Other sugars or carbohydrates, whether nutrientor not, can serve with the'saline to impart hypertonicity to the solution.
  • they are included in such amounts as to provide a hypertonicity above 320 milliosmoles, the latter being approximately isotonic to body solutions. 7 7
  • compositions of this invention in platelet deficiency therapy are interesting observations resulting from the in vivo use of compositions of this invention in platelet deficiency therapy. This appears to be due to a thrombo-plastic activity of the gelatin-matrix itself and is possibly accounted for by the fact that, during storage,
  • saidmatrix being maintained at a temperature of about 4 C., and substantially intact platelets discretely distributed throughout said matrix.
  • a therapeutic product suitable for injection into humans at body temperature, comprising a sterile gel of the following ingredients:
  • a solid matrix maintained at a temperature of about 4 C. but being liquid at human body temperature, comprising gelatin, water-soluble acetate salt, and viable .platelets discretely distributed throughout said matrix in a concentration exceeding 200,000 per mmfi, said matrix having a hypertonicity above 320 milliosmoles.
  • a solid matrix maintained at a temperature of about 4 C., but being liquid at human body temperature, comprising gelatin, water-soluble acetate salt, carbohydrate, chloride salt and viable platelets discretely distributed throughout said matrix in a concentration exceeding 200,000 per mm. said matrix having a hypertonicity above 320 milliosmoles.
  • Wintrobe Clinical Hematology, January 1949, pages 192 and 196.

Description

United States Patent PLATELET PRESERVATION James L. Tullis, Newton, Mass.
No Drawing. Application September to, 1952, Serial No. 308,951
4 Claims. (Cl. 167-78) This invention relates to the preservation of platelets outside the living body and, more particularly, to sterile therapeutically effective preparations containing platelets in concentrated form, suitable for in-vivo use as in the field of platelet deficiency therapy.
The primary object of this invention was to devise a means by which platelets could be stockpiled for in-vivo use in case of catastrophic atomic radiation, though such stockpiling for peace-time therapy is alone a worthy object. To this end, it was imperative that platelet integrity outside the human body be prolonged, inasmuch as prior to this invention the stability of intactnessin the sense of preservation of therapeutic eflectiveness-of platelets outside living bodies did not exceed three days. Further objects include the preservation of platelets in a form suitable for injection into a living body at high concentratio'ns, for therapeutic purposes.
In accordance with this invention, the duration of platelet integrity has been increased beyond the most optimistic expectations and now greatly exceeds the average in-vivo life span. No final figures on the ultimate time of satisfactory preservation can be given inasmuch as sufiicient time has not elapsed since the first platelets were successfully preserved to provide final data. Evidence thus far points to many months of satisfactory preservation.
This invention further provides a practical preservative medium for highly concentrated platelets; and the platelet-containing preservative is in water-soluble and,
hence, suitable and convenient form for direct injection into a living body.
Platelets preserved in accordance with this invention are derived from whole blood by any of a variety of separation methods. Though constituting no part of this invention, exemplary separation techniques are:
1. Whole blood treated to prevent clotting, as by the addition of citrate or other calcium sequestering agent, collected in a non-wettable surface sterile system and brought to a temperature near 0 C., may have its red and white cells sedimented with or Without the aid of 2. Whole blood may be passed, without the additionof citrate, over a cation exchange resin on the sodium cycle, some of which sites have been covered with calcium, resulting in a nearly quantitative separation from the whole blood of the platelets with the calcium of'the .blood. After the passage of the blood through the exchange resin, the platelets may be recovered fromthe exchange column by equilibrating the column with physiologi-c saline containing acetate ions and calcium complexing agents, all as described in an application of Edwin J. Cohn entitled Closed System for Continuous Separation of Components of Body Fluids, Serial No. 281,989, filed April 12, 1952.
The preservative medium of this invention may comprise an aqueous solution containing, per milliliters, about 0.2 gram of sodium acetate, about 5.0 grams glucose and about 0.9 gram sodium chloride. The wet platelet yield from 500 milliliters of whole blood (being the spontaneous sediment from the saline solutions after decanting the supernatant), is then gently stirred into this mixture which is maintained at about 4 C. To this mixture there is added sufiicient gelatin in a sterile pyrogen-free neutral aqueous solution so that, after standing, the composition will gel at a temperature of 4 C. In the case of a Knox gelatin of about 60,000 molecular weight and about midway with respect to gelatin frac- Gelatin Between 0.3 and 1.2 grams. Sodium chloride 0.36 gram.
Sodium acetate .08-O.2 gram. Carbohydrate (glucose)--. Not exceeding 2.0 grams. Platelets In excess of 200,000/mm.
By this procedure, approximately 50% of the original platelets of the blood can be recovered and discretely distributed through a medium having less than the volume of the whole blood. Since the concentration of platelets in average normal human blood is about 200,000 per cubic millimeter, the concentration is increased by a factor in the neighborhood of 5, but more important, of course, is their resulting stability for therapeutic purposes.
Where the separation of the platelets from the blood has taken place in a centrifuge, it is possible to use the preservative solution of this invention (before addition of the gelatin) as the eluting medium and, hence, avoid an intervening sedimentation step.
The gelled platelet-containing preservative can be stored at 4 C. and may be brought to a condition for in-vivo use simply by raising to body temperature, at which temperature the gelatin reverts to a non-viscid liquid.
It is understood that the preparations of this invention, when intended for in-vivo use, are prepared from sterilfl ized ingredients by aseptic techniques and using platelets derived from blood by aseptic and atraurnatic techniques.
The acetate anion acts as an anti-agglutina-te for the platelets. Other organic acid radicals function in a similar manner and may be added in water-soluble salt forniL. Only small amounts of such anti-agglutinating agents 1 need be present, as no benefits appear to be derived with concentrations about the rangeiof 0.2-0.5 gram per 100 milliliters.
V The glucose is an example of a hypertonicity-in-creasing agent. Other sugars or carbohydrates, whether nutrientor not, can serve with the'saline to impart hypertonicity to the solution. Preferably, they are included in such amounts as to provide a hypertonicity above 320 milliosmoles, the latter being approximately isotonic to body solutions. 7 7
An interesting observation resulting from the in vivo use of compositions of this invention in platelet deficiency therapy is the appearance of therapeutic effectiveness over and above that which would be expected solely from the number of injected platelets. This appears to be due to a thrombo-plastic activity of the gelatin-matrix itself and is possibly accounted for by the fact that, during storage,
water-soluble chloride and acetate salts, and glucose,
saidmatrix being maintained at a temperature of about 4 C., and substantially intact platelets discretely distributed throughout said matrix.
2. A therapeutic product, suitable for injection into humans at body temperature, comprising a sterile gel of the following ingredients:
Gelatin Between 0.3 and 1.2 grams. Sodium chloride .36 gram. Sodium acetate .08 to 0.2 gram. Carbohydrate Not exceeding 2.0 grams. Platelets In excess of 200,000 per mm. Water To total 40 cc.
maintained at a temperature of about 4 C., said product being liquid at human body temperature.
3. A solid matrix maintained at a temperature of about 4 C. but being liquid at human body temperature, comprising gelatin, water-soluble acetate salt, and viable .platelets discretely distributed throughout said matrix in a concentration exceeding 200,000 per mmfi, said matrix having a hypertonicity above 320 milliosmoles.
4. A solid matrix maintained at a temperature of about 4 C., but being liquid at human body temperature, comprising gelatin, water-soluble acetate salt, carbohydrate, chloride salt and viable platelets discretely distributed throughout said matrix in a concentration exceeding 200,000 per mm. said matrix having a hypertonicity above 320 milliosmoles.
References Cited inthe file of this patent UNITED STATES PATENTS 2,348,503 Taylor May 9, 1944 OTHER REFERENCES T Seldon: Anesthesiology, v01. 5, November 1944, pages a 566 to 573, particularly page 566.
Journal Biol. Chem., pages 210 to 211, January 1942.
Linzenmeier: Arch. ges. PhysioL, vol. 181 (1920), pages 178 to 183, particularly page 178.
Wintrobe: Clinical Hematology, January 1949, pages 192 and 196.
Nance: Journal Pharm. and Pharm., vol. 2, page 273, May 1950.
Taylor Oct. 22, 1940

Claims (1)

1. A THERAPEUTIC PRODUCT, SUITABLE FOR INJECTION INTO HAMANS AT BODY TEMPERATURE, COMPRISING A STERILE GELLED MATRIX CONSTITUTED OF AN AQUEOUS SOLUTION OF GELATIN, WATER-SOLUBLE CHORIDE AND ACETATE SALTS, AND GLUSCOSE, SAID MATRIX BEING MAINTAINED AT A TEMPERATURE OF ABOUT 4*C. AND SUBSTANTIALLY INTACT PLATELETS DISCRETELY DISTRIBUTE THROUGHOUT SAID MATRIX.
US308951A 1952-09-10 1952-09-10 Platelet preservation Expired - Lifetime US2786014A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US308951A US2786014A (en) 1952-09-10 1952-09-10 Platelet preservation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US308951A US2786014A (en) 1952-09-10 1952-09-10 Platelet preservation

Publications (1)

Publication Number Publication Date
US2786014A true US2786014A (en) 1957-03-19

Family

ID=23196040

Family Applications (1)

Application Number Title Priority Date Filing Date
US308951A Expired - Lifetime US2786014A (en) 1952-09-10 1952-09-10 Platelet preservation

Country Status (1)

Country Link
US (1) US2786014A (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928591A (en) * 1956-12-27 1960-03-15 Deaver George Lee Method and apparatus for separating particles in a fluid dispersion
DE1141747B (en) * 1959-10-16 1962-12-27 Dr Med Herbert Fischer Process for the preservation of living human and animal cells, preferably blood and blood components
DE1147004B (en) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Process for the preservation of living human or animal cell preparations, in particular blood and blood components
US3729947A (en) * 1970-12-04 1973-05-01 Alza Corp Process for storing blood platelets
US4447415A (en) * 1982-11-01 1984-05-08 Rock Gail A Plasma-free medium for platelet storage
EP0142339A1 (en) * 1983-11-09 1985-05-22 Thomas Jefferson University Method of and medium for storing blood platelets
US4695460A (en) * 1986-03-19 1987-09-22 American Red Cross Synthetic, plasma-free, transfusible platelet storage medium
WO1989002274A1 (en) * 1987-09-21 1989-03-23 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4828976A (en) * 1983-12-29 1989-05-09 Thomas Jefferson University Glucose free media for storing blood platelets
WO1991017655A1 (en) * 1990-05-17 1991-11-28 Cryopharm Corporation Novel lyophilized and reconstituted cell compositions
US5147776A (en) * 1990-02-26 1992-09-15 University Of Iowa Research Foundation Use of 2,5-anhydromannitol for control of pH during blood storage
US5340592A (en) * 1988-05-18 1994-08-23 Cobe Laboratories, Inc. Lyophilization of erythrocytes
US5425951A (en) * 1988-05-18 1995-06-20 Cryopharm Corporation Method of reconstituting lyophilized cells
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5487971A (en) * 1986-03-19 1996-01-30 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
WO2000025580A1 (en) * 1998-10-30 2000-05-11 Hyperbaric Systems Method and apparatus for preserving biological materials
WO2000053008A1 (en) * 1999-03-11 2000-09-14 Hyperbaric Systems Compositions and methods for preserving platelets
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20040018997A1 (en) * 1998-07-21 2004-01-29 Heather Reddy Inactivation of West Nile virus and malaria using photosensitizers
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20050019917A1 (en) * 2003-04-23 2005-01-27 Human Biosystems Methods and solutions for storing donor organs
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US20090191537A1 (en) * 2007-12-20 2009-07-30 Veronique Mayaudon Medium and methods for the storage of platelets
US20100081985A1 (en) * 2008-10-01 2010-04-01 Caridianbct, Inc. Platelet Additive Solution For Leukoreducing White Blood Cells In Apheresed Platelets
US9255261B2 (en) 2014-02-07 2016-02-09 Qol Medical Llc Ultrapure hypoallergenic solutions of sacrosidase
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218591A (en) * 1936-10-10 1940-10-22 Atlantic Coast Fisheries Co Vitamin preparation
US2348503A (en) * 1941-08-23 1944-05-09 Atlantic Coast Fisheries Co Vitamin preparation and method of making same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218591A (en) * 1936-10-10 1940-10-22 Atlantic Coast Fisheries Co Vitamin preparation
US2348503A (en) * 1941-08-23 1944-05-09 Atlantic Coast Fisheries Co Vitamin preparation and method of making same

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928591A (en) * 1956-12-27 1960-03-15 Deaver George Lee Method and apparatus for separating particles in a fluid dispersion
DE1141747B (en) * 1959-10-16 1962-12-27 Dr Med Herbert Fischer Process for the preservation of living human and animal cells, preferably blood and blood components
DE1147004B (en) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Process for the preservation of living human or animal cell preparations, in particular blood and blood components
US3729947A (en) * 1970-12-04 1973-05-01 Alza Corp Process for storing blood platelets
US4447415A (en) * 1982-11-01 1984-05-08 Rock Gail A Plasma-free medium for platelet storage
USRE32874E (en) * 1982-11-01 1989-02-21 Gail A. Rock Plasma-free medium for platelet storage
EP0142339A1 (en) * 1983-11-09 1985-05-22 Thomas Jefferson University Method of and medium for storing blood platelets
US4828976A (en) * 1983-12-29 1989-05-09 Thomas Jefferson University Glucose free media for storing blood platelets
US5487971A (en) * 1986-03-19 1996-01-30 American National Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4961928A (en) * 1986-03-19 1990-10-09 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4695460A (en) * 1986-03-19 1987-09-22 American Red Cross Synthetic, plasma-free, transfusible platelet storage medium
WO1989002274A1 (en) * 1987-09-21 1989-03-23 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US5425951A (en) * 1988-05-18 1995-06-20 Cryopharm Corporation Method of reconstituting lyophilized cells
US5340592A (en) * 1988-05-18 1994-08-23 Cobe Laboratories, Inc. Lyophilization of erythrocytes
US5648206A (en) * 1988-08-26 1997-07-15 Cobe Laboratories, Inc. Lyophilization of cells
US5213814A (en) * 1989-04-10 1993-05-25 Cryopharm Corporation Lyophilized and reconstituted blood platelet compositions
US5147776A (en) * 1990-02-26 1992-09-15 University Of Iowa Research Foundation Use of 2,5-anhydromannitol for control of pH during blood storage
WO1991017655A1 (en) * 1990-05-17 1991-11-28 Cryopharm Corporation Novel lyophilized and reconstituted cell compositions
US6566046B2 (en) 1992-03-02 2003-05-20 Baxter International Inc. Synthetic media for blood components
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US20030194806A1 (en) * 1992-03-02 2003-10-16 Lily Lin Synthetic media for blood components
US6866992B2 (en) 1992-03-02 2005-03-15 Baxter International Inc. Synthetic platelet storage media formulation
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US20040018997A1 (en) * 1998-07-21 2004-01-29 Heather Reddy Inactivation of West Nile virus and malaria using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US20020009705A1 (en) * 1998-10-30 2002-01-24 David O. Lucas Compositions, methods and apparatuses for preserving platelets
US6828090B2 (en) * 1998-10-30 2004-12-07 Human Biosystems Compositions, methods and apparatuses for preserving platelets
US7202020B2 (en) 1998-10-30 2007-04-10 Human Biosystems Compositions, methods and apparatuses for preserving platelets
US20040223957A1 (en) * 1998-10-30 2004-11-11 Lucas David O. Compositions, methods and apparatuses for preserving platelets
WO2000025580A1 (en) * 1998-10-30 2000-05-11 Hyperbaric Systems Method and apparatus for preserving biological materials
WO2000053008A1 (en) * 1999-03-11 2000-09-14 Hyperbaric Systems Compositions and methods for preserving platelets
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7901673B2 (en) 2000-06-02 2011-03-08 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US7892535B2 (en) 2000-06-02 2011-02-22 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US20100080781A1 (en) * 2000-06-02 2010-04-01 Caridianbct Biotechnologies, Llc Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US20040023201A9 (en) * 2000-11-28 2004-02-05 Mcburney Laura Storage solution containing photosensitizer for inactivation of biological contaminants
US20030186213A1 (en) * 2000-11-28 2003-10-02 Mcburney Laura Storage solution containing photosensitizer for inactivation of biological contaminants
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US7029839B2 (en) 2003-04-23 2006-04-18 Human Biosystems Methods and solutions for storing donor organs
US20050019917A1 (en) * 2003-04-23 2005-01-27 Human Biosystems Methods and solutions for storing donor organs
US20060121438A1 (en) * 2003-04-23 2006-06-08 Human Biosystems Methods and solutions for storing donor organs
US20090191537A1 (en) * 2007-12-20 2009-07-30 Veronique Mayaudon Medium and methods for the storage of platelets
US10358627B2 (en) 2007-12-20 2019-07-23 Fenwal, Inc. Medium and methods for the storage of platelets
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US20100081985A1 (en) * 2008-10-01 2010-04-01 Caridianbct, Inc. Platelet Additive Solution For Leukoreducing White Blood Cells In Apheresed Platelets
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
US10273456B2 (en) 2011-04-07 2019-04-30 Fenwal, Inc. Automated methods and systems for washing platelet concentrates
US9469847B2 (en) 2014-02-07 2016-10-18 Qol Medical Llc Ultrapure hypoallergenic solutions of sacrosidase
US9849161B2 (en) 2014-02-07 2017-12-26 Qol Medical Llc Ultrapure hypoallergenic solutions of sacrosidase
US9255261B2 (en) 2014-02-07 2016-02-09 Qol Medical Llc Ultrapure hypoallergenic solutions of sacrosidase
US10588947B2 (en) 2014-02-07 2020-03-17 Qol Medical Llc Ultrapure hypoallergenic solutions of sacrosidase

Similar Documents

Publication Publication Date Title
US2786014A (en) Platelet preservation
Humphrey et al. Absorption of serotonin (5-hydroxytryptamine) and histamine by dog platelets
JAFFE et al. Water binding in the articular cartilage of rabbits
JPS6156134A (en) Collagenous medicinal composition
US3864478A (en) Storage-stable hemoglobin solutions and method for their preparation
DE2655801A1 (en) METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION
Moyer et al. A Study of the Interrelationship of Salt Solutions Serum and Defibrinated Blood in the Treatment of Severely Scalded, Anesthetized Dogs
JPS63502107A (en) Solution to stabilize red blood cells during storage
PL86966B1 (en)
DE2742529A1 (en) PLASMINOGEN ACTIVATOR COMPLEX, PROCESS FOR ITS MANUFACTURING AND MEDICINAL PRODUCT CONTAINING IT
WO2017131130A1 (en) Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
Litwin et al. Hidden Acidosis Following Intravascular Red Blood Cell Aggregation in Dogs:*: Effects of High and Low Viscosity Dextran
CN105456182A (en) Topical cream for treating fungal infection and production method thereof
Cohn et al. Effect of blood sugar levels and insulin lack on gluconeogenesis by the kidney of the dog
DE1617279C3 (en) Process for the production of a preparation containing the Aspergillopeptidase ARL 1 from Aspergillus oryzae and a medicament containing it
Hernandez et al. Biochemical studies on the iguana
US9226898B1 (en) Submicron particles for the treatment of radiation damage in patients
US9987359B2 (en) Subcutaneous injection product for cattle for inducing superovulation
Zwemer Electrolyte and sugar determinations as indicators of adrenal influence on normal cell activity
US2145869A (en) Intravenous therapy for the treatment of syphilis
Olson et al. Investigation of the accompaniment of calcium during active calcium transport from human erythrocyte ghosts
Calesnick et al. Decrease in aerobic glycolysis of erythrocytes following the continuous administration of L-triiodothyronine
EP0123142B1 (en) Process for the stabilization of hematin
JPS5959625A (en) Stabilization of tumor encrosis factor
DE1929998C3 (en) Method of stabilizing blood